Review of fullerene toxicity and exposure - Appraisal of a human health risk assessment, based on open literature

Regulatory Toxicology and Pharmacology

Volumn 58, Issue 3, 2010, Pages 455-473

  Aschberger, Karin ^a   Johnston, Helinor J ^b,d   Stone, Vicki ^b   Aitken, Robert J ^c   Tran, C Lang ^c   Hankin, Steven M ^c   Peters, Sheona A K ^c   Christensen, Frans M ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^c INSTITUTE OF OCCUPATIONAL MEDICINE   (United Kingdom)

^d Chemicals and Nanotechnologies Division   (United Kingdom)

Author keywords

C60; Data gaps; Exposure; Fullerenes; Hazard; Nanoparticles; Risk; Risk assessment; Toxicity

Indexed keywords

COSMETIC; FULLERENE DERIVATIVE; ANTIOXIDANT;

ARTICLE; DECISION MAKING; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SOLUBILITY; ENVIRONMENTAL EXPOSURE; FEASIBILITY STUDY; GENOTOXICITY; HEALTH HAZARD; HUMAN; HYGIENE; INHALATION; LONG TERM EXPOSURE; MOLECULAR SIZE; NONHUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PRODUCT SAFETY; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; SKIN; SURFACE PROPERTY; TOXICITY TESTING; TOXICOKINETICS; WORKPLACE; DRUG SURVEILLANCE PROGRAM; HEALTH CARE POLICY; REVIEW; TIME;

ANTIOXIDANTS; CONSUMER PRODUCT SAFETY; COSMETICS; ENVIRONMENTAL EXPOSURE; FULLERENES; HEALTH POLICY; HUMANS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT; TIME FACTORS;

EID: 77957115833     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.08.017     Document Type: Article

References (101)

1. Aitken R.J., Chaudhry M.Q., Boxall A.B.A., Hull M. Manufacture and use of nanomaterials: current status in the UK and global trends. Occup. Med. 2006, 56:300-306.
2. Aoshima H., Kokubo K., Shirakawa S., Ito M.S., Yamana S., Oshima T. Antimicrobial activity of fullerenes and their hydroxylated derivatives. Biocontrol. Sci. 2009, 14(2):69-72.
3. Aoshima H., Saitoh Y., Ito S., Yamana S., Miwa N. Safety evaluation of highly purified fullerenes (HPFs): based on screening of eye and skin damage. J. Toxicol. Sci. 2009, 34(5):555-562.
4. Aschberger, K., Johnston, H.J., Stone, V., Aitken, R.J., Tran, C.L., Hankin, S.M., Peters, S.A.K., Christensen, F.M., 2010. Review of carbon nanotubes toxicity and exposure - appraisal of a human health risk assessment based on open literature. Crit. Rev. Toxicol., accepted for publication, doi:10.3109/10408444.2010.506638.
5. + reversions of salmonella typhimurium as an example. Russian Journal of Genetics (translated from Genetika) 2002, 38(4):453-457.
6. 60 fullerene nanoparticles and microparticles. Toxicol. Sci. 2008, 101(1):122-131.
7. 60. Bioorg. Chem. 1996, 24(4):376-385.
8. Buseck P.R., Tsipursky S.J., Hettich R. Fullerenes from the geological environment. Science 1992, 257(5067):215-217.
9. 24 protects mice from ionizing-radiation-induced immune and mitochondrial dysfunction. Toxicol. Appl. Pharmacol. 2010, 243(1):27-34.
10. Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J. Autoimmun. 2010, 34:J234-J246.
11. Chaudhuri P., Paraskar A., Soni S., Mashelkar R.A., Sengupta S. Fullerenol-cytotoxicity conjugates for cancer chemotherapy. ACS Nano. 2009, 3(9):2505-2514.
12. Chen B.X., Wilson S.R., Das M., Coughlin D.J., Erlanger B.F. Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. Proc. Natl. Acad. Sci. USA 1998, 95(18):10809-10813.
13. 22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett. 2005, 5(10):2050-2057.
14. 60 in rats. Toxicol. Pathol. 1998, 26(1):143-151.
15. Christensen, F.M., Johnston, H.J., Stone, V., Aitken, R.J., Hankin, S., Peters, S., Aschberger, K., (2010a). Nano titanium-dioxide - feasibility and challenges for human health risk assessment based on open literature. Nanotoxicology, doi:10.3109/17435390.2010.504899.
16. Christensen F.M., Johnston H.J., Stone V., Aitken R.J., Hankin S., Peters S., Aschberger K. Nano-silver - feasibility and challenges for human health risk assessment based on open literature. Nanotoxicology 2010, 4:284-295.
17. 60 fullerenes in water: evidence for genotoxicity. Environ. Sci. Technol. 2006, 40(23):7394-7401.
18. Donaldson K., Stone V. Current hypotheses on the mechanisms of toxicity of ultrafine particles. Ann. Ist. Super. Sanita. 2003, 39(3):405-410.
19. Dugan L.L., Lovett E.G., Quick K.L., Lotharius J., Lin T.T., O'Malley K.L. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat. Disord. 2001, 7(3):243-246.
20. EC (European Commission), 2003. Technical Guidance Document in support of Commission Directive 93/67/EEC on Risk Assessment for new notified substances, Commission Regulation (EC) No 1488/94 on Risk Assessment for existing substances and Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market. European Commission, Joint Research Centre. Available at: (last accessed 21.05.10). http://ecb.jrc.ec.europa.eu/tgd/.
21. ECHA (European Chemicals Agency), 2008. REACH Guidance on Information Requirements and Chemicals Safety Assessment. European Chemicals Agency. Available at: part F: (last accessed 21.05.10). http://www.guidance.echa.europa.eu.
22. Erlanger B.F., Chen B.X., Zhu M., Brus L. Binding of an anti-fullerene IgG monoclonal antibody to single wall carbon nanotubes. Nano Lett. 2001, 1(9):465-467.
23. 60 fullerenes and single-walled carbon nanotubes. Environ. Health. Perspect. 2009, 117(5):703-708.
24. Fujita K., Morimoto Y., Ogami A., Myojyo T., Tanaka I., Shimada M., Wang W.N., Endoh S., Uchida K., Nakazato T., Yamamoto K., Fukui H., Horie M., Yoshida Y., Iwahashi H., Nakanishi J. Gene expression profiles in rat lung after inhalation exposure to C(60) fullerene particles. Toxicology 2009, 258(1):47-55.
25. Fujitani Y., Kobayashi T., Arashidani K., Kunugita N., Suemura K. Measurement of the physical properties of aerosols in a fullerene factory for inhalation exposure assessment. J. Occup. Environ. Hyg. 2008, 5(6):380-389.
26. Gao, Z., Hedtke, B.M., Marsters, J.A., Lehman, M.R., Holmes, T., Lucak, J.F., Ferguson, L-J.C., McDonald, J.D., Walker, N.J., 2009 (Mar 15-19) Disposition of C60 Fullerene after Inhalation (nanoC60), Intratracheal Instillation, or Intravenous Injection in Male F344 Rats. Poster presented at the Society of Toxicology annual meeting, Baltimore, MD; , (last accessed 21.05.10). http://www.dspace.lrri.org:8080.
27. Gharbi N., Pressac M., Hadchouel M., Szwarc H., Wilson S.R., Moussa F. [60]Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005, 5(12):2578-2585.
28. 60 particles on CHO and MDCK cells. Scanning 2009, 30(2):213-220.
29. Huczko A., Lange H., Calko E. Fullerenes: experimental evidence for a null risk of skin irritation and allergy. Fullerene Sci. Technol. 1999, 7(5):935-939.
30. 24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials 2009, 30(6):1184-1196.
31. Ito S., Itoga K., Yamato M., Akamatsu H., Okano T. The co-application effects of fullerene and ascorbic acid on UV-B irradiated mouse skin. Toxicology 2010, 267(1-3):27-38.
32. Jacobsen N.R., Pojana G., White P., Moller P., Cohn C.A., Korsholm K.S., Vogel U., Marcomini A., Loft S., Wallin H. Genotoxicity, cytotoxicity, and reactive oxygen species induced by single-walled carbon nanotubes and C(60) fullerenes in the FE1-Mutatrade markMouse lung epithelial cells. Environ. Mol. Mutagen. 2008, 49(6):476-487.
33. Johnson D.R., Methner M.M., Kennedy A.J., Steevens J.A. Potential for occupational exposure to engineered carbon-based nanomaterials in environmental laboratory studies. Environ. Health. Perspect 2010, 118(1):49-54.
34. Johnston H.J., Hutchison G.R., Christensen F.M., Aschberger K., Stone V. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol. Sci. 2010, 114(2):162-182.
35. Kamat J.P., Devasagayam T.P.A., Priyadarsini K.I., Mohan H. Reactive oxygen species mediated membrane damage induced by fullerene derivatives and its possible biological implications. Toxicology 2000, 155(1-3):55-61.
36. 60 upon mutagenesis, phototoxicity, and permeability into the human skin tissue. Basic Clin. Pharmacol. Toxicol. 2009, 104:483-487.
37. 60 /liposome complex: defensive effects against UVA-induced damages in skin structure, nucleus and collagen type I/IV fibrils, and the permeability into human skin tissue. J. Photochem. Photobio. B. 2010, 98(1):99-105.
38. Kolosnjaj J., Swarc H., Moussa F. 13 Toxicity studies of fullerenes and derivatives" Bioapplications of nanoparticles 2007, 168-180. Landes Biosciences, Toronto. W.C. Chan (Ed.).
39. 60 Buckminsterfullerene. Nature 1985, 318(14):162-163.
40. Lens M. Use of fullerenes in cosmetics. Recent patents on Biotechnol. 2009, 3:118-123.
41. Liu, Y., Jiao, F., Qiu, Y., Li, W., Qu, Y., Tian, C., Li, Y., Bai, R., Lao, F., Zhao, Y., Chai, Z., Chen, C., 2009. Immunostimulatory properties and enhanced TNF-α mediated cellular immunity for tumor therapy by C60(OH)20 nanoparticles. Nanotechnol. 20(41), 415102. doi: 10.1088/0957-4484/20/41/415102.
42. 60). Biomaterials 2008, 29(26):3561-3573.
43. Maynard A.D., Baron P.A., Foley M., Shvedova A.A., Kisin E.R., Castranova V. Exposure to carbon nanotube material: aerosol release during the handling of unrefined single-walled carbon nanotube material. J. Toxicol. Environ. Health A 2004, 67(1):87-107.
44. Methner M., Hodson L., Geraci C. Nanoparticle Emission Assessment Technique (NEAT) for the identification and measurement of potential inhalation exposure to engineered nanomaterials-part A. J. Occup. Environ. Hyg. 2010, 7(3):127-132.
45. Methner M., Hodson L., Dames A., Geraci C. Nanoparticle Emission Assessment Technique (NEAT) for the identification and measurement of potential inhalation exposure to engineered nanomaterials-part b: results from 12 field studies. J. Occup. Environ. Hyg. 2010, 7(3):163-176.
46. Mitchell L.A., Lauer F.T., Burchiel S.W., McDonald J.D. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat. Nanotechnol. 2009, 4:451-456.
47. Mori T., Takada H., Ito S., Matsubayashi K., Miwa N., Sawaguchi T. Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. Toxicology 2006, 225(1):48-54.
48. Morimoto, Y., Hirohashi, M., Ogami, A., Oyabu, T., Myojo, T., Nishi, K.I., Kadoya, C., Todoroki, M., Yamamoto, M., Murakami, M., Shimada, M., Wang, W.N., Yamamoto, K., Fujita, K., Endoh, S., Uchida, K., Shinohara N., Nakanishi, J., Tanaka, I., 2010. Inflammogenic effect of well-characterized fullerenes in inhalation and intratracheal instillation studies. Part. Fibre Toxicol. 14(7), 4. doi: 10.1186/1743-8977-7-4.
49. 24 on the frequency of micronuclei and chromosome aberrations in CHO-K1 cells. Mutat. Res. 2009, 680(1-2):25-30.
50. 60 fullerene from the lung into the blood circulation in the mouse: possible association of diffusion and caveolaemediated pinocytosis. Toxicol. Pathol. 2009, 37(4):456-462.
51. Nielsen G.D., Roursgaard M., Jensen K.A., Poulsen S.S., Larsen S.T. In vivo biology and toxicology of fullerenes and their derivatives. Basic Clin. Pharmacol. Toxicol. 2008, 103(3):197-208.
52. Nikolić, N., Vranjes-Ethurić, S., Janković, D., Ethokić, D., Mirković, M., Bibić, N., Trajković, V., 2009 Preparation and biodistribution of radiolabeled fullerene C60 nanocrystals. Nanotechnol. 20(38), 385102. doi: 10.1188/0957-4484/20/38/385102.
53. 60) induce oxidative stress in the brain of juvenile largemouth bass. Environ. Health Perspect. 2004, 112(10):1058-1062.
54. Oberdörster G. Significance of particle parameters in the evaluation of exposure dose response relationships of inhaled particles. Inhal. Toxicol. 1996, 8(Suppl.):73-89.
55. Oberdörster G. Safety assessment for nanotechnology and nanomedicine: concepts on nanotoxicology. J. Intern. Med. 2010, 267(1):89-105.
56. Oberdörster G., Oberdörster E., Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 2005, 113(7):823-839.
57. Oberdörster G., Sharp Z., Atudorei V., Elder A., Gelein R., Kreyling W., Cox C. Translocation of inhaled ultrafine particles to the brain. Inhal. Toxicol. 2004, 16(6-7):437-445.
58. Park E.J., Kim H., Kim Y., Yi J., Choi K., Park K. Carbon fullerenes (C60s) can induce inflammatory responses in the lung of mice. Toxicol. Appl., Pharmacol. 2010, 244(2):226-233.
59. Pauluhn J. Retrospective analysis of 4-week inhalation studies in rats with focus on fate and pulmonary toxicity of two nanosized aluminium oxyhydroxides (boehmite) and pigment-grade iron oxide (magnetite): the key metric of dose is particle mass and not particle surface area. Toxicology 2009, 259(3):140-148.
60. Pauluhn J. Multi-walled carbon nanotubes (Baytubes®): approach for derivation of occupational exposure limit. Regul. Toxicol. Pharmacol. 2010, 57(1):78-89.
61. Radomski A., Jurasz P., Alonso-Escolano D., Drews M., Morandi M., Malinski T., Radomski M.W. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol. 2005, 146(6):882-893.
62. Roberts J.E., Wielgus A.R., Boyes W.K., Andley U., Chignell C.F. Phototoxicity and cytotoxicity of fullerol in human lens epithelial cells. Toxicol. Appl. Pharmacol. 2008, 228(1):49-58.
63. 60 fullerene (fullerenol) attenuates neutrophilic lung inflammation in mice. Basic Clin. Pharmacol. Toxicol. 2008, 103(4):386-388.
64. Rouse J.G., Yang J., Barron A.R., Monteiro-Riviere N.A. Fullerene-based amino acid nanoparticle interactions with human epidermal keratinocytes. Toxicol. In Vitro 2006, 20(8):1313-1320.
65. Rouse J.G., Yang J., Ryman-Rasmussen J.P., Barron A.R., Monteiro-Riviere N.A. Effects of mechanical flexion on the penetration of fullerene amino acid-derivatized peptide nanoparticles through skin. Nano Lett. 2007, 7(1):155-160.
66. Rushton E.K., Jiang J., Leonard S.S., Eberly S., Castranova V., Biswas P., Elder A., Han X., Gelein R., Finkelstein J., Oberdörster G. Concept of assessing nanoparticle hazards considering nanoparticle dosemetric and chemical/biological response metrics. J. Toxicol. Environ. Health, Part A 2010, 73(5):445-461.
67. Ryan J.J., Bateman H.R., Stover A., Gomez G., Norton S.K., Zhao W., Schwartz L.B., Lenk R., Kepley C.L. Fullerene nanomaterials inhibit the allergic response. J. Immunol. 2007, 179:665-672.
68. Sayes C.M., Fortner J.D., Guo W., Lyon D.Y., Boyd A.M., Ausman K., Tao Y.J., Sitharaman B., Wilson L.J., Hughes J.B., West J.L., Colvin V.L. The differential cytotoxicity of water-soluble fullerenes. Nano Lett. 2004, 4(10):1881-1887.
69. 60 cytotoxicity is due to lipid peroxidation. Biomaterials 2005, 26(36):7587-7595.
70. 60 water suspensions in rats: few differences in fullerene toxicity in vivo in contrast to in vitro profiles. Nano Lett. 2007, 7(8):2399-2406.
71. 60, its suspension in water, and its uptake by human keratinocytes. J. Am. Chem. Soc. 1994, 116(10):4517-4518.
72. 60-generated singlet oxygen dependent formation of lipid peroxides. Carcinogenesis 1996, 17(10):2163-2169.
73. 60 nanoparticles. Toxicol. lett. 2009, 191(2-3):289-296.
74. Shinohara, N., Gamo, M. Nakanishi, J., 2009a. Risk assessment of manufactured nanomaterials - fullerene (C60) - NEDO project " Research and Development of Nanoparticle Characterizations Methods" Interim Report issued October 16, 2009; available at , (last accessed 21.06.10). http://www.aist-riss.jp.
75. Simeonova, P., 2007. Nanoparticle exposure and systemic/cardiovascular effects - experimental data. In: Proceedings of the NATO advanced research workshop on nanotechnology - toxicology issues and environmental safety, Springer, pp. 53-64.
76. Simeonova P., Erdely A. Engineered nanoparticle respiratory exposure and potential risks for carciovascular toxicity: predictive tests and biomarkers. Inhal. Toxicol. Suppl. 2009, 1:68-73.
77. Singh N., Manshian B., Jenkins G.J.S., Griffiths S.M., Williams P.M., Maffeis T.G.G., Wright C.J., Doak S.H. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials 2009, 30:3891-3914.
78. 60 fullerene: a powerful antioxidant or a damaging agent? The importance of an in-depth material characterization prior to toxicity assays. Environ. Pollut. 2009, 157(4):1134-1139.
79. Tabata Y., Murakami Y., Ikada Y. Photodynamic effect of polyethylene glycol-modified fullerene on tumour. Jpn. J. Cancer Res 1997, 88(11):1108-1116.
80. Takada H., Mimura H., Xiao L., Islam R.M., Matsubayashi K., Ito S., Miwa N. Fullerene (INCI #: 7587) is as " Radical Sponge" on the skin. Its high level of safety, stability and potential as premier anti-aging and whitening cosmetic ingredient. Fullerenes, Nanotubes Carbon Nanostruct. 2006, 14(2-3):335-341.
81. +/- mouse by intraperitoneal application of multi-wall carbon nanotube. J. Toxicol. Sci. 2008, 33(1):105-116.
82. Totsuka Y., Higuchi T., Imai T., Nishikawa A., Nohmi T., Kato T., Masuda S., Kinae N., Hiyoshi K., Ogo S., Kawanishi M., Yagi T., Ichinose T., Fukumori N., Watanabe M., Sugimura T., Wakabayashi K. Genotoxicity of nano/microparticles in in vitro micronuclei, in vivo comet and mutation assay systems. Part. Fibre Toxicol. 2009, 6:23.
83. Tran C.L., Buchanan D., Cullen R.T., Searl A., Jones A.D., Donaldson K. Inhalation of poorly soluble particles II. Influence of particle surface area on inflammation and clearance. Inhal. Toxicol. 2000, 12:1113-1126.
84. Tsuchiya T., Oguri I., Yamakoshi Y.N., Miyata N. Novel harmful effects of [60]fullerene on mouse embryos in vitro and in vivo. FEBS Lett. 1996, 393(1):139-145.
85. 60 exposure elicits an oxidative stress response in embryonic zebrafish. Toxicol. Appl. Pharmacol. 2008, 229(1):44-55.
86. Utsunomiya S., Jensen K.a., Keeler G.J., Ewing R.C. Uraninite and fullerene in atmospheric particulates. Environ. Sci. Technol. 2002, 36(23):4943-4947.
87. Walker, N.J., 2009. The toxicology of fullerenes: current efforts at the national toxicology program. National Toxicology Program, National Institute of Environmental Health Sciences, NIH, preliminary results reported at: , (last accessed 21.05.10); Testing information >> testing Status of Agents at NTP >> testing status: nanoscale material (Fullerene-C60 1 micron) M070010; , (last accessed 21.05.10). http://www.ntp.niehs.nih.gov.
88. Wang I.C., Tai L.A., Lee D.D., Kanakamma P.P., Shen C.K., Luh T.Y., Cheng C.H., Hwang K.C. C(60) and water-soluble fullerene derivatives as antioxidants against radical-initiated lipid peroxidation. J. Med. Chem. 1999, 42(22):4614-4620.
89. Xia T., Kovochich M., Brant J., Hotze M., Sempf J., Oberley T., Sioutas C., Yeh J.I., Wiesner M.R., Nel A.E. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 2006, 6(8):1794-1807.
90. 60) topically exposed in industrial organic solvents. Toxicol. Appl. Pharmacol. 2010, 242(1):29-37.
91. Xiao L., Matsubayashi K., Miwa N. Inhibitory effect of the water-soluble polymer-wrapped derivative of fullerene on UVA-induced melanogenensis via downregulation of tyrosinase expression in human melanocytes and skin tissues. Arch. Dermatol. Res. 2007, 299(5-6):245-257.
92. Xiao L., Takada H., Gan X., Miwa N. The water-soluble fullerene derivative " Radical Sponge® exerts cytoprotective action against UVA irradiation but not visible-light-catalyzed cytotoxicity in human skin keratinocytes. Bioorg. Med. Chem. Lett. 2006, 16(6):1590-1595.
93. Xu J.Y., Han K., Li S.X., Cheng J.S., Xu G.T., Li W.X., Li Q.N. Pulmonary responses to polyhydroxylated fullerenols, C(60)(OH)(x). J. Appl. Toxicol. 2009, 29(7):578-584.
94. 14C labelling, absorption, distribution, excretion and acute toxicity. Chem. Biol. 1995, 2(6):385-389.
95. Yamawaki H., Iwai N. Cytotoxicity of water-soluble fullerene in vascular endothelial cells. Am. J. Physiol. Cell Physiol. 2006, 290(6):C1495-C1502.
96. Yeganeh B., Kull C.M., Hull M.S., Marr L.C. Characterization of airborne particles during production of carbonaceous nanomaterials. Environ. Sci. Technol. 2008, 42(12):4600-4606.
97. Yin J.-J., Lao F., Fu P.P., Wamer W.G., Zhao Y., Wang P.C., Qiu Y., Sun B., Xing G., Dong J., Liang X.-J., Chen C. The scavenging of reactive oxygen species and the potential for cell protection by functionalised fullerene materials. Biomaterials 2009, 30(4):611-612.
98. Yin J.J., Lao F., Meng J., Fu P.P., Zhao Y., Xing G., Gao X., Sun B., Wang P.C., Chen C., Liang X.J. Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger. Mol. Pharmacol. 2008, 74(4):1132-1140.
99. Zhou Z., Lenk R., Dellinger A., MacFarland D., Kumar K., Wilson S.T., Kepley C.L. Fullerene nanomaterials potentiate hair growth. Nanomedicine 2009, 5(3):202-207.
100. 60) and fullerol. Environ. Toxicol. Chem. 2008, 26(5):976-979.
101. 60) on tumor cell growth in vitro and in vivo and a possible role of immunosuppression in the cancer-promoting activity of C(60). Biomaterials 2009, 30(36):6940-6946.